Bob is a SVP of the Trout Group. He focuses on the Sino-US cross-border banking and strategic consulting service (mainly licensing) and investor relations.  Prior to joining Trout in September 2016, he was managing director, senior biotech analyst at WallachBeth Capital.  Before that, he was the CFO of Aoxing Pharmaceuticals, a NYSE MKT listed Chinese specialty pharmaceutical company.  He has also served as Principal in crossover life science private equity firm Merlin Nexus and senior equity analysts at assets management firms Bennett Lawrence and Merlin Biomed Group.

​

Bob received his PhD and MBA from Penn State University and did postdoctoral training at University of Pennsylvania.  He has published eight articles in peer-reviewed scientific journals.  He also won the prestigious Ray Wu scholarship for outstanding Chinese Student to study abroad. Bob holds Series 7, 63, 79, 86, and 87 securities licenses.